Case Study: Revolutionizing Retinal Disease Treatment with Gene Therapy: An Insight into Regenxbio’s Retinal Pipeline
Time: 2:30 pm
day: Day 1- Clinical 2
Details:
• Utilizing its proprietary NAV AAV platform to develop therapies targeting rare and prevalent retinal diseases, offering potential long-term, one-time treatments
• Key candidates include RGX-314, aimed at treating wet AMD and diabetic retinopathy, designed to reduce the need for frequent anti-VEGF injections, showing promising clinical data
• Regenxbio’s retinal pipeline targets not only large patient populations but also rare genetic disorders, emphasizing their mission to transform care in retinal disease through precision medicine
